Updates
** Shares of vaccine makers rise after FDA leaders' comments on new guidelines for approval of COVID boosters
** Shares of Moderna MRNA.O up 8.5% at $28.62, Pfizer PFE.N up 2.2% at $23.50 and Novavax NVAX.O up 1.5% at $7.86
** U.S. FDA plans to mandate new placebo-controlled clinical trials for approval of annual COVID boosters for Americans under 65 in good health
** For adults over the age of 65 years, data, FDA can approve based on data from tests that measure immune response in patients
** "In the big picture this actually eases some investor concern for 2025 guidance to some extent," Jefferies analyst Michael Yee says
** FDA advisers also scheduled to discuss on Thursday whether to recommend COVID-19 vaccines for 2025-26 for targeting the LP.8.1 subvariant
** LP.8.1 strain is spreading faster than other variants, becoming dominant in different parts of the world, including the U.S. and Europe
** Including session's moves, MRNA down 31.6%, PFE down 11.5% and NVAX down 2.9% YTD
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。